| Business Summary | | Epimmune
Inc.
is
engaged
in
the
development
of
novel
vaccines
for
the
treatment
and
prevention
of
infectious
diseases
and
cancer.
The
Company
is
in
preclinical
development
with
therapeutic
vaccines
for
breast,
colon,
lung
and
prostate
cancers,
hepatitis
C,
hepatitis
B
and
HIV,
and
prophylactic
vaccines
for
hepatitis
C,
HIV
and
malaria.
The
Company
expects
that
a
therapeutic
vaccine
targeting
HIV
will
be
the
first
of
its
candidate
vaccines
to
enter
human
clinical
trials.
The
Company
expects
initial
clinical
studies
for
this
vaccine
candidate
to
be
initiated
by
late
2001
or
early
2002. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | Epimmune
Inc.,
discovers,
designs
and
develops
new
drugs
for
the
effective
treatment
of
acute
and
chronic
inflammatory
diseases,
infectious
diseases
and
cancer.
For
the
six
months
ended
6/30/01,
revenues
rose
from
$691
thousand
to
$2.2
million.
Net
loss
rose
4%
to
$2.3
million.
Revenues
reflect
higher
research
and
development
contracts
and
license
fees.
Higher
loss
reflects
increased
R&D
expenses
due
to
higher
costs
for
HIV
grant
program
and
related
equipment
and
facility. | More
from
Market Guide: Significant
Developments |
| | | | FY2000 Pay | |
| Howard Greene, Jr., 58 Chairman | -- | Emile Loria, M.D., 51 Pres,
CEO, Director | -- | Robert De Vaere, 43 CFO,
VP-Fin. | -- | Robert Chesnut, Ph.D., 57 Exec.
VP, R&D and Sec. | $221K | Mark Newman, Ph.D., 46 VP,
Infectious Disease Program | 161K | Dollar amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|